In this exclusive interview on Healthcare Unfiltered, I welcome Dr. Patrick Soon-Shiong, a Chinese immigrant who grew up under apartheid in South Africa and …
Robotic Repair of Bile Duct Injury
On Second Wind: The Boomer & Gunnar Esiason Story, watch on as a father advocates to inspire change on his son’s cystic fibrosis battle. ✔️…
Watch ‘The First Cell: A New Dialogue on Medicine, Art, and Science’! The session features Dr. Azra Raza, renowned Oncologist, Professor, and Author of The…
A risk classification system using C-reactive protein (CRP) levels and hypercalcemia is “useful for predicting the outcomes” of patients receiving enfortumab vedotin.
David Morris, MD, FACS, of Urology Associates of Nashville, discusses the emerging role of copper-based PSMA imaging agents, specifically Clarity Pharmaceuticals’ 64Cu-SAR-bisPSMA.
The phase 3 AMPLIFY study provides evidence that fixed-duration acalabrutinib plus venetoclax may be a valid treatment option for fit patients with treatment-naive CLL.
AbstractBackgroundDonor-recipient heart size matching is crucial in heart transplantation; however, the often-used predicted heart mass (PHM) ratio may be inaccurate in the setting of obesity.Objec…
The retrospective analysis reaffirmed evidence from CCTG BR.34 that showed bone metastasis was associated with worse outcomes in ICI-treated NSCLC, with or without chemotherapy.
A study evaluated kidney outcomes of angiotensin receptor-neprilysin inhibitor therapy versus ACEI/ARB for thrombotic microangiopathy related to malignant hypertension.
